Immunocore Holdings PLC Sponsored ADR

IMCR Healthcare Biotechnology

Immunocore Holdings PLC Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $400.0 million, up 29.0% from fiscal 2024. In the quarter to June 2026, revenue grew 18.3%, EPS grew 92.1%, free cash flow fell 40.7% and total debt was flat, each against the same quarter a year earlier. Revenue growth for three consecutive years.

29.40 0.08 −0.27%
Market cap
$1.5B
P/E
0.0×
Fwd P/E
208×
Dividend yield
—
F-score
3/9
Altman Z
1.52
Beneish M
−2.40
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
Piotroski F-Score

+8 more TTM periods

6 3 3 3
ROE
(7.55%) (9.58%) (7.14%) (4.47%)
ROA
(2.67%) (3.42%) (2.63%) (1.64%)
ROIC
0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
(3.39%) (4.66%) (3.55%) (2.18%)
Average Days of Receivables
72.96 67.50 71.68 80.79
Free Cash Flow per Share
0.06 (0.30) (0.61) (0.81)
Free Cash Flow
2.99 (15.05) (30.74) (41.15)
Other line items

Show all line items

Columns are period end dates